1. Home
  2. BGLC vs BCDA Comparison

BGLC vs BCDA Comparison

Compare BGLC & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

HOLD

Current Price

$1.61

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Logo BioCardia Inc.

BCDA

BioCardia Inc.

HOLD

Current Price

$1.12

Market Cap

14.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGLC
BCDA
Founded
2017
N/A
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3M
14.1M
IPO Year
2019
2009

Fundamental Metrics

Financial Performance
Metric
BGLC
BCDA
Price
$1.61
$1.12
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
9.4K
162.2K
Earning Date
04-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
45.78
N/A
EPS
N/A
N/A
Revenue
$7,424,911.00
$479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$0.75
52 Week High
$6.10
$2.27

Technical Indicators

Market Signals
Indicator
BGLC
BCDA
Relative Strength Index (RSI) 42.89 56.90
Support Level $1.23 $0.78
Resistance Level $1.88 $1.26
Average True Range (ATR) 0.12 0.06
MACD -0.00 -0.00
Stochastic Oscillator 32.81 50.73

Price Performance

Historical Comparison
BGLC
BCDA

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: